1
Chen, Yi Hsuan, Blommestein, Hedwig M., Klazenga, Reinder, Uyl-de Groot, Carin, van Vulpen, Marco
Veröffentlicht in: Chen , Y H , Blommestein , H M , Klazenga , R , Uyl-de Groot , C & van Vulpen , M 2023 , ' Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands ' , Cancers , vol. 15 , no. 2 , 516 . https://doi.org/10.3390/cancers15020516;
2023
Veröffentlicht in: Chen , Y H , Blommestein , H M , Klazenga , R , Uyl-de Groot , C & van Vulpen , M 2023 , ' Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands ' , Cancers , vol. 15 , no. 2 , 516 . https://doi.org/10.3390/cancers15020516;
2023
2
3
4
5
Blommestein, Hedwig M., de Groot, Saskia, Aarts, Mieke J., Vemer, Pepijn, de Vries, Robin, van Abeelen, Annet F. M., Posthuma, E. F. M. Ward, Uyl-de Groota, Carin A.
Veröffentlicht in: Blommestein , H M , de Groot , S , Aarts , M J , Vemer , P , de Vries , R , van Abeelen , A F M , Posthuma , E F M W & Uyl-de Groota , C A 2016 , ' Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands ' , Leukemia Research , vol. 50 , pp. 37-45 . https://doi.org/10.1016/j.leukres.2016.09.005;
2016
Veröffentlicht in: Blommestein , H M , de Groot , S , Aarts , M J , Vemer , P , de Vries , R , van Abeelen , A F M , Posthuma , E F M W & Uyl-de Groota , C A 2016 , ' Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands ' , Leukemia Research , vol. 50 , pp. 37-45 . https://doi.org/10.1016/j.leukres.2016.09.005;
2016
6
de Groot, Saskia, van der Linden, Naomi, Franken, Margreet G., Blommestein, Hedwig M., Leeneman, Brenda, van Rooijen, Ellen, (Koos) van der Hoeven, J.J.M., Wouters, Michel W., Westgeest, Hans M., Uyl-de Groot, Carin A.
Veröffentlicht in: Value in Health ; volume 20, issue 4, page 627-636 ; ISSN 1098-3015;
2017
Veröffentlicht in: Value in Health ; volume 20, issue 4, page 627-636 ; ISSN 1098-3015;
2017